Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Current Deferred Revenue (2020 - 2025)

Historic Current Deferred Revenue for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Q2 2025 value amounting to $2.6 million.

  • Maravai Lifesciences Holdings' Current Deferred Revenue rose 2115.56% to $2.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $2.6 million, marking a year-over-year increase of 2115.56%. This contributed to the annual value of $3.3 million for FY2024, which is 4000.0% down from last year.
  • Per Maravai Lifesciences Holdings' latest filing, its Current Deferred Revenue stood at $2.6 million for Q2 2025, which was up 2115.56% from $3.5 million recorded in Q1 2025.
  • Over the past 5 years, Maravai Lifesciences Holdings' Current Deferred Revenue peaked at $120.7 million during Q1 2021, and registered a low of $1.9 million during Q3 2024.
  • Its 5-year average for Current Deferred Revenue is $21.0 million, with a median of $5.0 million in 2022.
  • In the last 5 years, Maravai Lifesciences Holdings' Current Deferred Revenue tumbled by 9560.89% in 2022 and then soared by 2115.56% in 2025.
  • Over the past 5 years, Maravai Lifesciences Holdings' Current Deferred Revenue (Quarter) stood at $12.6 million in 2021, then crashed by 61.9% to $4.8 million in 2022, then grew by 14.58% to $5.5 million in 2023, then plummeted by 40.0% to $3.3 million in 2024, then fell by 21.21% to $2.6 million in 2025.
  • Its Current Deferred Revenue stands at $2.6 million for Q2 2025, versus $3.5 million for Q1 2025 and $3.3 million for Q4 2024.